Regeneron Pharmaceuticals: Carcinoma, Non-Small-Cell Lung trials

The registry lists 17 Carcinoma, Non-Small-Cell Lung studies with Regeneron Pharmaceuticals as lead sponsor. 3 are open to participants now and 6 have results posted.

Phase 1 6Phase 2 9Phase 3 4No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on TumorsNot yet recruitingNCT07863024Phase 1/2
• A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingNCT07154290Phase 2
• An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in EuropeRecruitingNCT05363319
• A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic CancerTerminatedNCT04916002Phase 2Results posted
• REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung CancerTerminatedNCT03515629Phase 3Results posted
• A Study of REGN2810 and Ipilimumab in Patients With Lung CancerTerminatedNCT03430063Phase 2Results posted
• Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung CancerCompletedNCT03409614Phase 3Results posted
• Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)CompletedNCT03088540Phase 3Results posted
• A Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Participants With Advanced CarcinomaTerminatedNCT00794417Phase 1/2Results posted
• A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT06465329Phase 2
• Expanded Access Use of Cemiplimab in Patients With Solid TumorsApproved for marketingNCT06132191
• A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung CancerActive, not recruitingNCT05800015Phase 2/3
• Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced CancerTerminatedNCT04982224Phase 1
• A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung CancerActive, not recruitingNCT04077099Phase 1/2
• Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult PatientsActive, not recruitingNCT03916627Phase 2
• Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT03580694Phase 1
• Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung CancerCompletedNCT03438318Phase 1